Chiesi Group and Oak Hill Bio Collaborate on OHB-607, a Neonatal Therapy
Chiesi Group, an international biopharmaceutical and healthcare group, and Oak Hill Bio, a neonatology and rare disease therapeutics company, have entered into a License and Development Agreement for OHB-607, a clinical-stage investigational drug designed to address complications associated with extremely premature birth.
OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a crucial element for fetal growth and development, along with its binding protein, IGFBP-3. Babies born at less than 28 weeks gestational age often have low levels of IGF-1, increasing their risk of severe bronchopulmonary dysplasia (BPD), a condition that may lead to chronic lung disease. Currently, there are no approved medications to prevent BPD in pre-term infants. OHB-607, as a replacement for human IGF-1, aims to prevent BPD and its long-term respiratory consequences.
Giuseppe Accogli, CEO of Chiesi Group, expressed the importance of addressing complications of prematurity with an innovative solution, emphasizing the potential benefits for extremely premature babies. OHB-607 presents a potential breakthrough for BPD, a condition with significant unmet medical needs in neonatology.
Chiesi and Oak Hill Bio plan to resume a Phase 2b clinical trial for OHB-607 in 2024, covering the United States, Europe, and Japan. Previous clinical studies have shown the drug’s potential to significantly reduce the risk of severe BPD.
Josh Distler, President and Chief Financial Officer of Oak Hill Bio, believes that OHB-607 could be a groundbreaking therapy for extremely preterm infants, comparable to the impact of lung surfactants approved over 30 years ago. The collaboration with Chiesi, known for its expertise in neonatology, is expected to accelerate the development and delivery of this promising therapy to patients.
Related posts:
Innovent Biologics and Sanegene Bio to Collaborate on Innovative siRNA Drug for Hypertension Treatment
Astellas and Poseida Forge Pact for Novel Off-the-Shelf CAR-T Therapy
Novartis Secures Groundbreaking $100 Million Deal with Voyager for Cutting-Edge Gene Therapy Partnership
MiMedx Group Receives FDA Warning Letter for Axiofill; Shares Decline 7%
